Overview

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Status:
NOT_YET_RECRUITING

Trial end date:
2032-02-22

Target enrollment:

Participant gender:

Summary

This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

Phase:

PHASE3

Details

Lead Sponsor:

Pfizer

Treatments:

abrocitinib